Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Baxalta Inc.
Headquarters: Bannockburn, IL, United States of America
Website: N/A
Year Founded: 2015
Status: Acquired
BioCentury | Nov 14, 2024
Management Tracks
New CEOs at Valo, Apriori
Plus: Glasspool to lead VarmX, Novartis vet Eissa joins Cellares and updates from Mestag, Andera, Incyclix and more
BioCentury | Aug 7, 2024
Management Tracks
Flagship adds White House veteran Panjabi
Plus: Biogen alum Radhakrishnan joins Sofinnova Investments, and updates from Bicycle, iTeos, Fennec, Faron and ORIC
BioCentury | May 10, 2023
Deals
How CTI found its target population and set itself up for a $1.7B takeout by Sobi
Swedish company pays 89% premium to add Vonjo to hematology portfolio, a year after its accelerated approval in a disease space dominated by Jakafi
BioCentury | Oct 26, 2020
Deals
Bayer’s $2B deal for AskBio follows biotech’s decision to bet on its own pipeline
Deal gives Bayer gene therapy programs, manufacturing and technologies
BioCentury | Apr 3, 2020
Deals
Servier adds mAb platform via takeout of former European biotech darling Symphogen
BioCentury | Mar 19, 2020
Emerging Company Profile
OncoOne: targeting oxidized MIF for solid tumors
Led by Shire vets, the Austrian biotech is taking aim at a highly selective tumor antigen the biotech left behind
BioCentury | Nov 4, 2019
Clinical News
Halozyme to focus on Enhanze partnering after Phase III oncology miss
BioCentury | Sep 27, 2019
Finance
Via Munich office, Kurma launches oncology company Tacalyx
French VC’s company creation office in Munich yields first start-up, a Max Planck Institute spinout
BioCentury | Sep 6, 2019
Regulation
Lackluster U.S. biosimilars market sparks radical recommendations
The U.S. biosimilars market isn’t living up to its promise, prompting calls for rethinking the regulatory paradigm
Items per page:
1 - 10 of 152